J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding
Johnson & Johnson’s Ollin Biosciences acquisition comes with a Phase 3-ready bispecific antibody. The companies say this eye drug offers advantages over Vabysmo, a Roche drug approved for wet age-related macular degeneration and diabetic macular edema.
The Permanente Medical Group Launches Innovation Company To Commercialize Clinicians’ Ideas
Kaiser Permanente's physician organization, the largest physician-led medical group in the country, is launching a healthcare innovation company meant to help grow clinicians' ideas into healthcare realities.
A Complete Medical Record Still Won’t Fix Prior Authorization
The chart may be complete, and two parties may still reach different conclusions. The issue is not always what they know; it is how the organization interprets what it knows.
Safety and Regulation Must Lead the Way in Healthcare AI Innovation
By applying proven and enforceable guardrails, coupled with smart financial incentives, we can ensure AI elevates medical care while maintaining the trust that holds our health system together.
Ongoing Check-Ins Can Help More Postpartum Mothers Get the Care They Need
Engaging with mothers earlier gives us the best chance of catching PPD, PPA, and PPP before they escalate. It won’t be perfect, but it will help more moms and their families.